Effectiveness of Tai Chi vs Cognitive Behavioural Therapy for Insomnia in Middle-Aged and Older Adults
November 27, 2025
Brand Name :
Wellferon, LelF A
Synonyms :
Interferon alpha-2, interferon alpha-A
Class :
Immunotherapy/antineoplastic/antiviral
Dosage Forms & StrengthsÂ
Injectable solutionsÂ
3MU/1mlÂ
5MU/1mlÂ
10MU/1mlÂ
3MU subcutaneous or intramuscular, thrice daily for up to 48 weeks
Initial dose: 1.26- 6MU/sq.mt once a day subcutaneous or intramuscular for 1 to 4 weeks:
Maintenance dose: 2.5- 5MU/sq.mt thrice a week for upto six months
Dosage Forms & StrengthsÂ
Safety and efficacy study is not establishedÂ
Refer to adult dosingÂ
the risk of adverse effects may be increased
the risk of bleeding may be increased
the rate of metabolism of acenocoumarol may be reduced
the rate of metabolism of acetaminophen may be reduced
the risk of adverse effects may be increase
the risk of adverse effects may be increased
allogeneic processed thymus tissueÂ
the therapeutic activity of allogenic processed thymus tissue may be reduced
the risk of adverse effects may be increased
the rate of metabolism of alosetron may be reduced
the risk of adverse effects may be increased
the rate of metabolism of aminophylline may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of bleeding may be increased
the risk of bleeding may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of infection may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of thrombocytopenia and neutropenia may be increased
Actions and spectrum:Â
Type I interferon receptors like IFNAR1 and IFNAR2c are bound by interferon alpha, and these receptors activate and dimerize two Jak Janus kinases and tyrosine kinases namely Jak1 and Tyk2. These phosphorylate receptors and transphosphorylate themselves.
Following their binding to Stat1 and 2, which are transcription activators and signal transducers, the phosphorylated INFAR receptors activate and dimerize many (about 100)antiviral and immunomodulatory proteins. Compared to interferon beta, interferon alpha binds to interferon receptors of type I less stably.Â
Frequency not definedÂ
HypotensionÂ
EdemaÂ
AlopeciaÂ
Dry skinÂ
DepressionÂ
ChillsÂ
InsomniaÂ
Irritability Â
HeadacheÂ
HypocalcemiaÂ
Suppression of bone marrowÂ
Hemolytic anemiaÂ
Visual disturbancesÂ
Pulmonary congestionÂ
ProteinuriaÂ
Hearing changesÂ
BloatingÂ
Sexual dysfunctionÂ
Throat irritationÂ
Irregular menstruationÂ
AngioedemaÂ
Acute renal failureÂ
Ischaemic attackÂ
Black Box Warning Â
Never operate machinery or drive a vehicleÂ
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Chronic hepatitisÂ
EpilepsyÂ
Renal impairmentÂ
Myocardial infarctionÂ
Arrhythmia Â
Thyroid disorderÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: CÂ
Lactation:Â Â
The data about the excretion of interferon alfa-n1 into breast milk is not known. Â
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Pharmacodynamics:Â
It increases the effectiveness of peptides derived from viral antigens by upregulating the expression of MHC I proteins. This improves the macrophage’s suitability for CTL-mediated killing by boosting the activation of CD8+ T cells, which are the progenitors of cytotoxic T lymphocytes (CTLs). In addition, interferon alpha stimulates the production of multiple essential antiviral mediators, such as protein kinase R and 2′-5′ oligoadenylate synthetase (2′-5′ A synthetase).Â
Pharmacokinetics:
limited ADME data is available Â
AbsorptionÂ
80% of the drug administered intramuscularly or subcutaneously is absorbed. The time to obtain peak serum concentration is 15min to 60 minutesÂ
Half-life:Â
1.2 hours, as noticed in an invitro study with mammalian reticulocytesÂ
Administration:Â
To be administered as advised by the physicianÂ
Patient information leafletÂ
Generic Name: interferon alfa- n1Â Â
Why do we use interferon alfa- n1?Â
A purified form of human interferon called interferon alfa-n1 is used to treat genital warts caused by the human papillomavirus by promoting the innate antiviral response.Â